1. Market Research
  2. > Pathology
34 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-?, CXCR4, CSF-1R, CD47-SIRP?, adenosine pathway & STING 2018

  • $ 912
  • July 2018
  • 204 pages

ClinicalTrials. gov June 2018 - Phase ## Study of MK-## Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab for Patients With Advanced/ Metastatic Solid Tumors or Lymphomas.

  • Lymphoma
  • Therapy
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • Incyte Corporation

Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update

  • $ 513
  • November 2017
  • 58 pages

Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update  The Competitive Intelligence Report „Anti-VEGF & Anti-VEGF-R ...

  • Lymphoma
  • Therapy
  • Genentech, Inc.
  • Novartis AG
  • Roche Group

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

  • $ 798
  • November 2016
  • 80 pages

The Cancer and Leukemia Group B (CALGB) Lymphoma Committee conducted a phase II study of the epratuzumab - rituximab combination in ## untreated patients with follicular lymphoma (Grant, 2013).

  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Monoclonal Antibody
  • United States

TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

  • $ 2793
  • August 2016
  • 388 pages

Mantle cell lymphoma; lung cancer Precl Message Product MACROGENICS - ##/ ## ID No.

  • Cancer
  • Immunotherapy
  • Lymphoma
  • Affimed Therapeutics AG
  • Amgen Inc.

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

  • $ 342
  • May 2016
  • 74 pages

MAA CD## Antibody ## ## CT-P##; rituximab Advanced follicular lymphoma Rec chimeric mab.

  • Biosimilar
  • Lymphoma
  • Biogen Idec Inc.
  • Boehringer Ingelheim GmbH
  • Celltrion, Inc.

Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

  • $ 570
  • June 2016
  • 180 pages

Mantle cell lymphoma; lung cancer Precl Message Product MACROGENICS - ##/ ## ID No.

  • Cancer
  • Immunotherapy
  • Lymphoma
  • Affimed Therapeutics AG
  • Amgen Inc.

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

  • $ 1482
  • May 2016
  • 462 pages

ClinicalTrials. gov May 2016 - A phase Ib/ II study evaluating the safety and efficacy of atezolizumab in combination with obinutuzumab plus lenalidomide in patients with relapsed or refractory follicular lymphoma Message I/ II R/ R follicular lymphoma in combination wi

  • Biosimilar
  • Lymphoma
  • Pharmaceutical
  • Pfizer Inc.
  • Roche Group

CD123: a paradigmatic target for immunotherapeutic treatment modalities

  • $ 798
  • August 2016
  • 83 pages

CD##-expressing Hodkgin lymphoma (HL) cell lines were sensitive to SL-## in a concentration-dependent manner.

  • Immunotherapy
  • Lymphoma
  • United States
  • Cellectis S.A.
  • Janssen Biotech, Inc.

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

  • $ 2700
  • June 2019
  • 463 pages

IN JULY 2018, THE FIRST PATIENT WAS DOSED IN THE PHASE I/ II STUDY OF GEN## IN B-CELL MALIGNANCIES INCLUDING DIFFUSE LARGE B-CELL LYMPHOMA, HIGH-GRADE B-CELL LYMPHOMA, PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA, FOLLICULAR LYMPHOMA, MANTLE CELL

  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Pharmaceutical
  • Therapy

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

  • $ 2350
  • May 2020
  • 195 pages

B-CELL LYMPHOMA EXTRA LARGE (BCL-XL) IS A WELL-VALIDATED CANCER TARGET.

  • Drug Development
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals an industry analysis of technologies, stakeholders, deals & trends

  • $ 2451
  • May 2018
  • 294 pages

Clinical studies with KTE-C## in upside indications are ongoing: ##nd line diffuse large B-cell lymphoma (ZUMA-## study); ##/ ## ______________________________________________________________________________ indolent non-Hodkgin lymphoma (ZUMA-##); mantle cell lymphoma

  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Therapy
  • Adaptimmune Therapeutics plc

Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases

  • $ 900
  • June 2019
  • 121 pages

The emerging data includes patients with R/ R diffuse large B-cell lymphoma (DLBCL) who had progressed after CAR-T therapy.

  • Biopharmaceutical
  • Immunotherapy
  • Lymphoma
  • Targeted Delivery
  • Targeted Therapy

Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

  • $ 570
  • July 2018
  • 78 pages

Combination therapy dose escalation in solid tumors is underway, as is monotherapy dose escalation in lymphomas.

  • Lymphoma
  • Therapy

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update

  • $ 456
  • February 2016
  • 46 pages

For more information, please contact sales@lamerie. com Related Competitor Analysis Reports Competitor Analysis: Focal Adhesion Kinase (FAK) Inhibitor Competitor Analysis: Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors Competitor Analysis: Anaplastic Lymphoma Kinase (ALK) Inhibitors Competi

  • Lymphoma
  • Targeted Therapy
  • Therapy
  • United States
  • Eli Lilly & Co.

Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

  • $ 684
  • June 2018
  • 89 pages

The antibody was more effective than the combination of anti-CD## and anti-PD-L## antibodies in the BCL## lymphoma model.

  • Lymphoma
  • Medical Biotechnology
  • Therapy
  • Product Initiative
  • HengRui Medicine Co., Ltd.

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

  • $ 1083
  • February 2016
  • 88 pages

Treating tumorspecific T cells with an RORγ agonist in vitro significantly enhanced the cells' ability to regress large and established lymphoma and melanoma tumors in vivo.

  • Lymphoma
  • Pharmaceutical
  • United States
  • 4SC Discovery GmbH
  • Advinus

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

  • $ 2350
  • September 2019
  • 223 pages

Sensitivity to eFT## was associated with dosedependent decreases in the oncogenic drivers c-MYC, CCND##/ ##, BCL## or MCL-## in ABC (activated B-Cell) and GCB (germinal center B-cell) DLBCL (Diffuse Large B-cell Lymphoma) subtypes and Burkitt' s lymphoma. eFT## has good pharm

  • Genomics
  • Lymphoma
  • RNA
  • RNAi Technology
  • Therapy

Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab

  • $ 342
  • March 2015
  • 62 pages

Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy III Rec fully human IgG## mab Novartis (from GlaxoSmith- Kline (GSK) / Genmab) Antibody Relapsed or refractory follicular lymphoma (FL) Product ONCOBIOLOGICS ID No.

  • Lymphoma
  • Medical Biotechnology
  • Biogen Idec Inc.
  • Boehringer Ingelheim GmbH
  • Genentech, Inc.

Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

  • $ 570
  • June 2018
  • 84 pages

lymphomas that are refractory to available therapy Locally advanced/ unres ectable or metastatic solid tumors or lymphomas that are refractory to available therapy or for which no standard therapy is available I Symphogen PR May ##, 2018 - Symphogen has enrolled the first patie

  • Cancer Immunotherapy
  • Lymphoma
  • Therapy
  • Product Initiative
  • Bristol-Myers Squibb Company

Competitor Analysis: NY-ESO-1-Targeted Immunotherapy

  • $ 456
  • June 2018
  • 72 pages

In the Phase I lymphoma study, they saw complete responses (CRs) in ##-##% of evaluable patients, a rate comparable to the best reported CAR-T studies in lymphoma, but without relapses.

  • Biopharmaceutical
  • Cell Therapy
  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
View report >

Lymphoma Statistics in the UK

  • January 2018
  • 6 pages

(observed and ##. ##% five years from a lymphoma diagnosis in 2009-2013.

  • Cancer
  • Lymphoma
  • United Kingdom
  • Demographic

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on